Opioid Peptides Protect Heart Cells From Death Through Delta and Kappa Receptors via KATP Channels
Delta-opioid (met-enkephalin) and kappa-opioid (dynorphin A) receptor activation protected isolated heart cells from simulated ischemia through KATP channel opening — the same protective mechanism as ischemic preconditioning.
Quick Facts
What This Study Found
Delta-opioid (met-enkephalin) and kappa-opioid (dynorphin A) receptor activation protected cardiomyocytes from simulated ischemia through KATP channel opening, confirming the opioid-KATP cardioprotection pathway.
Key Numbers
How They Did This
In-vitro study using freshly isolated adult rabbit cardiomyocytes. Simulated ischemia with selective opioid agonists, receptor antagonists, and KATP channel blockers to dissect the protective mechanism.
Why This Research Matters
Understanding exactly how opioid peptides protect the heart enables development of cardiac-specific opioid drugs that prevent heart attack damage without affecting the brain.
The Bigger Picture
The heart has its own opioid protection system that mimics ischemic preconditioning. This natural defense can be pharmacologically enhanced to prevent heart attack damage — a major therapeutic opportunity.
What This Study Doesn't Tell Us
Isolated cell model. Cardiomyocyte protection in vitro may not predict whole-heart or in-vivo protection. The interaction between delta and kappa pathways was not fully explored.
Questions This Raises
- ?Could cardiac-selective delta/kappa agonists prevent infarction?
- ?Does the protection work post-ischemia (post-conditioning) as well as pre-ischemia?
- ?Do patients on glibenclamide (diabetics) lose this cardiac opioid protection?
Trust & Context
- Key Stat:
- Two opioid receptors protect Both delta (enkephalin) and kappa (dynorphin) activation protected heart cells through KATP channels — the same mechanism as ischemic preconditioning
- Evidence Grade:
- Preliminary in-vitro evidence with clear receptor and channel specificity from selective pharmacological blocking in isolated cardiomyocytes.
- Study Age:
- Published in 2003. The opioid-KATP cardiac protection pathway has been confirmed and is a recognized cardioprotective mechanism.
- Original Title:
- Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.
- Published In:
- American journal of physiology. Heart and circulatory physiology, 285(3), H1032-9 (2003)
- Authors:
- Cao, Zhiping, Liu, Lijuan, Van Winkle, Donna M
- Database ID:
- RPEP-00800
Evidence Hierarchy
Frequently Asked Questions
Does the heart protect itself with opioids?
Yes. The heart has opioid receptors (delta and kappa) that, when activated by natural opioid peptides, open protective KATP channels. This is the same mechanism as ischemic preconditioning — the heart's built-in defense.
Could diabetics on glibenclamide be at risk?
Potentially — glibenclamide blocks KATP channels. This study shows the opioid heart protection requires KATP channels. Diabetics on glibenclamide might lose this natural cardiac defense, which has clinical implications.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00800APA
Cao, Zhiping; Liu, Lijuan; Van Winkle, Donna M. (2003). Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.. American journal of physiology. Heart and circulatory physiology, 285(3), H1032-9.
MLA
Cao, Zhiping, et al. "Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.." American journal of physiology. Heart and circulatory physiology, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Activation of delta- and kappa-opioid receptors by opioid pe..." RPEP-00800. Retrieved from https://rethinkpeptides.com/research/cao-2003-activation-of-delta-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.